0001193125-26-115878
SEC filingLarimar Therapeutics, Inc. (LRMR), a clinical-stage biotech focused on nomlabofusp for Friedreich's ataxia, reported a FY 2025 net loss of $165.7 million, widening from $80.6 million in 2024, primarily due to surging research and development expenses of $154.2 million (up from $73.3 million) driven by nomlabofusp manufacturing scale-up, clinical studies, and process qualification. General and administrative expenses rose slightly to $18.3 million from $17.6 million. Total operating expenses reached $172.5 million, with loss from operations at -$172.5 million, partially offset by $6.8 million in other income, net (down from $10.3 million). Balance sheet reflects total assets of $145.8 million, including $85.4 million in cash and equivalents, $51.4 million in short-term marketable securities (total liquidity $136.9 million), and stockholders' equity of $78.1 million. Cash flow showed $113.2 million used in operations, $100.3 million provided by investing (marketable securities maturities), and $65.1 million from financing via common stock issuance. Post-period February 2026 offering added $107.6 million net proceeds, extending runway into Q2 2027 to support BLA submission in June 2026 seeking accelerated approval.
Larimar Therapeutics reported FY 2025 results with a net loss of $165.7 million, up from $80.6 million in 2024, reflecting accelerated investment in its lead candidate nomlabofusp. Operating expenses totaled $172.5 million, a $81.6 million increase YoY, driven by R&D at $154.2 million (up $80.9 million) for manufacturing, clinical trials, and regulatory activities, and G&A at $18.3 million (up $0.7 million). Loss from operations was -$172.5 million, with other income net of $6.8 million. Basic and diluted EPS was -$3 on 73.2 million weighted-average shares. Total comprehensive loss was -$165.8 million, including -$94K unrealized loss on marketable securities. Balance sheet ended with $145.8 million total assets and $78.1 million equity.
No revenue was generated in FY 2025, consistent with pre-commercial status. The company remains focused on clinical development of nomlabofusp, with no product sales or collaboration revenue disclosed.
As a development-stage biotech with no revenue, gross and operating margins are not applicable. Operating expenses as a percentage of liquidity highlight high burn, with R&D comprising 89% of total op ex ($154.2M / $172.5M). Stock-based compensation was $7.0 million, contributing to expense increases. Net loss per share remained at -$3 basic and diluted.
Net cash used in operating activities was $113.2 million, up from $70.8 million in 2024, due to higher R&D and working capital changes (accrued expenses up $37.6M, prepaids down $6.7M). Investing provided $100.3 million from $184.0M marketable securities maturities net of $83.6M purchases and $91K capex. Financing yielded $65.1 million from stock issuance. Cash, equivalents, and restricted cash ended at $28.1 million, but total liquidity (incl. $51.4M short-term securities) was $136.9 million. Liabilities totaled $67.8 million, mostly current $64.8M. Equity components: common stock $83K, APIC $512.8M, accumulated deficit -$434.8M.
Management anticipates current cash of $136.9 million plus $107.6 million from February 2026 offering funds operations into Q2 2027. Key priorities include OL study topline data Q2 2026, BLA submission June 2026 for accelerated approval using skin FXN as surrogate endpoint, and Phase 3 initiation mid-2026. Risks include clinical delays, anaphylaxis mitigation, regulatory hurdles, and cash burn; potential need for additional funding if delays occur.